Mark A. Lewis, MD

Articles

A panel of 6 experts on colorectal cancer

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

April 11th 2024

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Unmet Needs Surrounding mCRC Treatment

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

April 11th 2024

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

Richard Kim, MD, an expert on colorectal cancer

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

April 4th 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD;Scott Paulson, MD

April 4th 2024

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 28th 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Considerations for Platinum-based Therapy

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 28th 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 21st 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 21st 2024

Side effect profiles driven by fruquintinib use are discussed.

Camidge and Lewis Discuss the Perspective of Being Both a Patient and Physician

D. Ross Camidge, MD, PhD;Mark A. Lewis, MD

March 14th 2024

Drs Camidge and Lewis discuss how Dr Lewis’ MEN-1 diagnosis has affected his professional life and the importance of seeking patient perspectives.

Consideration for Fruquintinib Dosing and Titration

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 14th 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 14th 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 7th 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

FRESCO-2 Study Highlights

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 7th 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

February 29th 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Fruquintinib MoA and Toxicity Profile Overview

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

February 29th 2024

Key safety considerations for the use of fruquintinib are explored.

Evaluating 3L Treatment Landscape Evolution

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

February 22nd 2024

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Overview of Current mCRC Treatment Landscape

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

February 22nd 2024

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

Caroline Seymour;Brian Rini, MD;Jonathan C. Trent, MD, PhD;Maryam Lustberg, MD, MPH;Pamela L. Kunz, MD;Jason Luke, MD;Mark A. Lewis, MD

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.